Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials

Creative Commons License

KALAFAT E., ŞÜKÜR Y. E., Abdi A., Thilaganathan B., Khalil A.

ULTRASOUND IN OBSTETRICS & GYNECOLOGY, vol.52, no.6, pp.706-714, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 52 Issue: 6
  • Publication Date: 2018
  • Doi Number: 10.1002/uog.19084
  • Journal Name: ULTRASOUND IN OBSTETRICS & GYNECOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.706-714
  • Keywords: hypertension, metformin, pre-eclampsia, prevention, weight gain, POLYCYSTIC-OVARY-SYNDROME, PREECLAMPSIA, INSULIN, ASPIRIN, PLACEBO, MELLITUS, OUTCOMES, PRETERM, MANAGEMENT, GLYBURIDE
  • Middle East Technical University Affiliated: No

Abstract

Objective Metformin has been reported to reduce the risk of pre-eclampsia. It is also known to influence soluble fms-like tyrosine kinase-1 level, which correlates significantly with the gestational age at onset and severity of pre-eclampsia. The main aim of this systematic review and meta-analysis of randomized trials was to determine whether metformin use is associated with the incidence of hypertensive disorders of pregnancy (HDP).